Evidence map›Paper›PMID 42067641›Full record

ArticleAnnals of hematology2026

CD135 (FLT3 receptor) expression as an indicator of prognosis in patients with de novo acute myeloid leukemia.

Jinhong Nie, Lu Gao, Yingchun Shao, Li Yang, Junjie Cao, Jinge Xu, Yuhang Wang, Yuqi Zhang, Tong Cui, Shiyuan Zhou and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jinhong Nie *Hematology Department, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou, China.
Lu Gao *Hematology Department, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou, China.
Yingchun Shao *Soochow Hopes Hematonosis Hospital, Suzhou, China.
Li Yang *Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Junjie Cao *Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Jinge Xu *Department of Hematology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yuhang WangHematology Department, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou, China.
Yuqi ZhangHematology Department, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou, China.
Tong CuiHematology Department, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou, China.
Shiyuan ZhouHematology Department, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou, China.
Wenjuan ZhuHematology Department, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou, China.
Mingqing ZhuHematology Department, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou, China.
Xiao MaHematology Department, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou, China.
Depei WuHematology Department, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou, China. drwudepei@163.com.
Xiaojin WuHematology Department, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou, China. wuxiaojin@suda.edu.cn.

Funding

the National Natural Science Foundation of China Grant No 82170172 and 82170222
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) blasts often have high CD135 (FLT3 receptor) expression, but its clinical impact is unclear. We analyzed CD135 expression, and the clinical characteristics and outcomes of 214 patients with de novo AML diagnosed between October 2022 and May 2024. Subsequently, we collected data on additional 78 patients, diagnosed with AML at four medical centers from June to December 2024, for external validation. The high-CD135-expression group had significantly lower CD34 surface expression (p = 0.003) and higher CD33 expression (p = 0.014) on AML blasts. The high-CD135-expression group also showed a higher frequency of NPM1 (p < 0.001) and DNMT3A (p = 0.032) mutations, but was not significantly associated with CD135 expression (p = 0.229). The patients in the high-CD135-expression group had lower initial induction therapy response rates than those in the low-CD135-expression group (p < 0.001). High CD135 expression was independently associated with poorer OS and PFS. In the subgroup of patients with high CD135 expression and FLT3-ITD mutations, those who received TKI combined with chemotherapy had significantly better OS (p = 0.007). Then we developed a prognostic nomogram incorporating CD135 expression. This model performed well both in the development cohort (area under the curve [AUC] = 0.817) and multicenter validation cohort (AUC = 0.722). CD135 expression on AML blasts is a pivotal marker that integrates molecular pathogenesis with clinical outcomes, highlighting its dual role as a prognostic indicator and therapeutic target in precision clinical approaches for AM.

Indexed as

Biomarkers, Tumorfms-Like Tyrosine Kinase 3Gene Expression Regulation, LeukemicLeukemia, Myeloid, AcuteAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMutationNucleophosminPrognosisYoung AdultBiomarkers, TumorFLT3 protein, humanfms-Like Tyrosine Kinase 3NPM1 protein, humanNucleophosminAcute myeloid leukemiaCD135 (FLT3 receptor) expressionInduction therapyNomogramOverall survival

Identifiers

PMID42067641
PMCPMC13134979

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.